Laurus Labs gets USFDA EIR for Visakhapatnam facility

Published On 2023-06-16 07:00 GMT   |   Update On 2023-06-16 07:00 GMT

Hyderabad: Laurus Labs has announced that the Company has received the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for the formulations manufacturing facility Unit–2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.The USFDA had conducted the inspection from 6th February, 2023 to 10th February, 2023 and issued Form 483 with...

Login or Register to read the full article

Hyderabad: Laurus Labs has announced that the Company has received the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for the formulations manufacturing facility Unit–2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.

The USFDA had conducted the inspection from 6th February, 2023 to 10th February, 2023 and issued Form 483 with two observations for the said facility.

Read also: Laurus Labs gets 2 USFDA observations for Visakhapatnam facility

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

"Further to our intimation dated February 10, 2023, on the Inspection conducted by the United States Food & Drug Administration (USFDA) at our formulations manufacturing facility Unit–2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh from 6th February, 2023 to 10th February, 2023, we wish to inform you that the Company has received the Establishment Inspection Report (EIR) from USFDA." the Company stated in a BSE filing.

Read also: Laurus Labs to buy additional stake of 7.24 percent in Immunoadoptive Cell Therapy for Rs 80 Crore

Laurus Labs is an Indian pharmaceutical company headquartered in Hyderabad. The Company's major focus areas include anti-retroviral, Hepatitis C, and Oncology drugs.

Most of the Laurus Labs manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA, etc. 

Read also: Laurus Labs bags USFDA nod for Paediatric ARV Oral Dispersible Film drug Dolutegravir in HIV/AIDS treatment

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News